Insulin signaling pathway mediators (Insulin signaling pathway)

The insulin signaling pathway mediators comprise a complex network of proteins responsible for transducing the signal from extracellular insulin to intracellular metabolic and growth effects. The process begins with insulin binding to the Insulin Receptor (INSR), a receptor tyrosine kinase, which undergoes autophosphorylation and recruits Insulin Receptor Substrate (IRS) proteins. These mediators then activate the Phosphoinositide 3-kinase (PI3K)/Akt pathway, which is the primary branch for glucose uptake via GLUT4 translocation, glycogen synthesis, and lipogenesis. Dysregulation of these mediators is the hallmark of insulin resistance and Type 2 diabetes, where the signaling efficiency is impaired despite the presence of the hormone. Pharmacological intervention focuses on enhancing the sensitivity of these mediators or bypassing defects to restore glucose homeostasis. Because this entry refers to a broad pathway rather than a single molecular target, it is classified as 'incorrect' for specific target mapping purposes.

Other names

Insulin signaling cascadeInsulin receptor signaling pathwayPI3K/Akt insulin pathway

Drugs targeting this pathway typically act as insulin mimetics, insulin sensitizers (increasing the efficiency of downstream mediators like IRS-1), or inhibitors of enzymes that negatively regulate the pathway (such as DPP-4 or SGLT2).